Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal

Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet